KEI Memo on U.S. Legislation to cap price increases on prescription drugs and to enhance the transparency of R&D costs

On April 30, 2019, KEI issued a memorandum to Congress concerning recent proposed measures to cap drug price increases and to increase the transparency of pharmaceutical research and development costs.  Congress is currently considering several bills that touch on these… Continue Reading

KEI asks HHS to use Bayh-Dole rights in Zinbryta patent (drug for multiple sclerosis)

Attached is a letter sent on September 14, 2017 to Andrew Bremberg, an Assistant to the President and the Director of the Domestic Policy Council at the White House, and Keagan Lenihan, a Senior Adviser to HHS Secretary Tom Price, regarding Zinbrytra (INN: daclizumab), a drug to approved by the FDA to treat multiple sclerosis. (PDF version here)

Continue Reading

July 6, 2001 letter from DHHS Secretary Tommy G. Thompson letter to Ralph Nader Regarding WHO rights to use inventions funded by the NIH

July 6, 2001 Mr. Ralph Nader P.O. Box 19312 Washington, D.C. 20036 Dear Mr. Nader: I am writing in response to the letter from you and your colleagues requesting that the Department of Health and Human Services (HHS) grant the… Continue Reading